General
Preferred name
BAMBUTEROL
Synonyms
BAMBUTEROL HYDROCHLORIDE ()
(¡À)-Bambuterol hydrochloride ()
KWD-2183 ()
(¡À)-Bambuterol ()
(??)-Bambuterol hydrochloride ()
KWD-2183 hydrochloride ()
Bambuterol HCl ()
(??)-Bambuterol ()
levobambuterol ()
(±)-Bambuterol hydrochloride ()
Bambuterol hydrochloride,KWD-2183 hydrochloride ()
Bambuterol (hydrochloride) ()
P&D ID
PD009511
CAS
81732-65-2
81732-46-9
Tags
prodrug
natural product
drug
available
First approval
1990
Drug indication
Asthma
Drug Status
investigational
approved
Max Phase
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Bambuterol has marketing approval in many countries but is not approved for sale in the US or UK.
(GtoPdb)
DESCRIPTION
Bambuterol is a long acting beta-adrenoceptor agonist (LABA) and is used in the treatment of asthma. It is an ester prodrug of the ß2-adrenergic agonist terbutaline. lt is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people with renal impairment. It can prolong the time of parent drug action. It has a strong role in bronchial dilation and used for obstructive airway diseases, such as bronchial asthma, chronic bronchitis, tremor and cardiac side effects. It has the adverse effects, including fatigue, nausea, palpitations, headache, dizziness and tremor. lt was developed by the Astra company and has been listed in 1987.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Bambuterol is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
24
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
48
Molecular Weight
367.21
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
1
Aromatic Ring Count
1
cLogP
2.23
TPSA
91.34
Fraction CSP3
0.56
Chiral centers
1.0
Largest ring
6.0
QED
0.83
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Adrenergic Receptor
AChR
??-adrenergic receptor
¦Â-adrenergic receptor
ADRB2, BCHE
Pathway
Neuronal Signaling
GPCR/G protein
Neuroscience
MOA
AChR agonist
Adrenergic Receptor antagonist
Adrenergic Receptor agonist
Indication
asthma
Therapeutic Class
Bronchodilator Agents
Solubility
in DMSO > 10 Mm
Source data
